JP2020529841A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529841A5 JP2020529841A5 JP2019572798A JP2019572798A JP2020529841A5 JP 2020529841 A5 JP2020529841 A5 JP 2020529841A5 JP 2019572798 A JP2019572798 A JP 2019572798A JP 2019572798 A JP2019572798 A JP 2019572798A JP 2020529841 A5 JP2020529841 A5 JP 2020529841A5
- Authority
- JP
- Japan
- Prior art keywords
- car
- seq
- host cell
- protein
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (17)
- 抗原認識ドメインと、膜貫通（ＴＭ）ドメインと、Ｔ細胞活性化ドメインとを含むキメラ抗原受容体（ＣＡＲ）であって、Ｂ細胞成熟抗原（ＢＣＭＡ）に対する抗原特異性を有し、前記抗原認識ドメインが、
（ａ）配列番号１〜３、
（ｂ）配列番号４〜６、
（ｃ）配列番号７〜９、又は
（ｄ）配列番号１０〜１２
のアミノ酸配列を含むＣＡＲ。 - 前記ＣＡＲの全てのドメインがヒトのである、請求項１に記載のＣＡＲ。
- 前記抗原認識ドメインが、約８〜約４０アミノ酸残基の長さを有するリンカーペプチドを含まない、請求項１又は２に記載のＣＡＲ。
- 前記ＣＡＲが抗体軽鎖可変領域を含まない、請求項１〜３のいずれか一項に記載のＣＡＲ。
- 前記抗原認識ドメインが、
（ａ）配列番号１３、
（ｂ）配列番号１４、
（ｃ）配列番号１５、又は
（ｄ）配列番号１６
のアミノ酸配列を含む、請求項１〜４のいずれか一項に記載のＣＡＲ。 - 前記Ｔ細胞活性化ドメインが、以下のタンパク質のうちのいずれか１つのＴ細胞シグナル伝達ドメインを含む、請求項１〜５のいずれか一項に記載のＣＡＲ：ヒトＣＤ２８タンパク質、ヒトＣＤ３−ゼータタンパク質、ヒトＦｃＲγタンパク質、ＣＤ２７タンパク質、ＯＸ４０タンパク質、ヒト４−１ＢＢタンパク質、ヒト誘導性Ｔ細胞共刺激タンパク質（ＩＣＯＳ）、前述のいずれかの改変バージョン、又は前述の任意の組み合わせ。
- 配列番号１７〜２８のいずれか１つのアミノ酸配列を含む、請求項１〜６のいずれか一項に記載のＣＡＲ。
- 請求項１〜７のいずれか一項に記載のＣＡＲをコードしているヌクレオチド配列を含む核酸。
- 配列番号２９〜４０のいずれか１つのヌクレオチド配列を含む、請求項８に記載の核酸。
- 請求項８又は９に記載の核酸を含むベクター。
- 請求項１０に記載のベクターを含む単離された宿主細胞。
- 前記宿主細胞がＴ細胞である、請求項１１に記載の単離された宿主細胞。
- 前記宿主細胞がナチュラルキラー（ＮＫ）細胞である、請求項１１に記載の単離された宿主細胞。
- 請求項１１〜１３のいずれか一項に記載の少なくとも１つの宿主細胞を含む細胞の集団。
- 請求項１〜７のいずれか一項に記載のＣＡＲ、請求項８若しくは９に記載の核酸、請求項１０に記載のベクター、請求項１１〜１３のいずれか一項に記載の宿主細胞、又は請求項１４に記載の集団、及び医薬的に許容し得る担体を含む、医薬組成物。
- 哺乳類におけるがんを治療又は予防するための医薬組成物であって、請求項１〜７のいずれか一項に記載のＣＡＲ、請求項８若しくは９に記載の核酸、請求項１０に記載のベクター、請求項１１〜１３のいずれか一項に記載の宿主細胞、請求項１４に記載の集団、又は請求項１５に記載の医薬組成物を含む、医薬組成物。
- 前記がんが、多発性骨髄腫又はホジキンリンパ腫である、請求項１６に記載の医薬組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023020373A JP2023071729A (ja) | 2017-06-30 | 2023-02-13 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527556P | 2017-06-30 | 2017-06-30 | |
| US62/527,556 | 2017-06-30 | ||
| PCT/US2018/039917 WO2019006072A1 (en) | 2017-06-30 | 2018-06-28 | CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020373A Division JP2023071729A (ja) | 2017-06-30 | 2023-02-13 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529841A JP2020529841A (ja) | 2020-10-15 |
| JP2020529841A5 true JP2020529841A5 (ja) | 2021-08-05 |
| JP7288405B2 JP7288405B2 (ja) | 2023-06-07 |
Family
ID=63350586
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Active JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2023020373A Pending JP2023071729A (ja) | 2017-06-30 | 2023-02-13 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020373A Pending JP2023071729A (ja) | 2017-06-30 | 2023-02-13 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200138865A1 (ja) |
| EP (2) | EP3645568B1 (ja) |
| JP (2) | JP7288405B2 (ja) |
| KR (1) | KR20200049757A (ja) |
| CN (1) | CN111094345B (ja) |
| AU (1) | AU2018291128A1 (ja) |
| CA (1) | CA3068444A1 (ja) |
| ES (1) | ES2928296T3 (ja) |
| IL (1) | IL271597B2 (ja) |
| SG (1) | SG11201913175TA (ja) |
| WO (1) | WO2019006072A1 (ja) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765342B2 (en) | 2012-04-11 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| KR20190053835A (ko) | 2016-06-21 | 2019-05-20 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
| CN117567624A (zh) | 2017-06-20 | 2024-02-20 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20200018498A (ko) | 2017-06-20 | 2020-02-19 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| KR20200116917A (ko) * | 2017-12-20 | 2020-10-13 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| US11873336B2 (en) | 2017-12-22 | 2024-01-16 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| MA55372A (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
| AR119746A1 (es) | 2019-06-14 | 2022-01-05 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| UY39191A (es) | 2020-04-29 | 2021-11-30 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
| CN115894703A (zh) | 2020-04-29 | 2023-04-04 | 特尼奥生物股份有限公司 | 具有经修饰重链恒定区的多特异性重链抗体 |
| CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
| CA3200509A1 (en) | 2020-12-31 | 2022-07-07 | Sonja SCHREPFER | Methods and compositions for modulating car-t activity |
| AU2022206324A1 (en) | 2021-01-11 | 2023-07-20 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| CA3219352A1 (en) | 2021-05-19 | 2022-11-24 | Sonja SCHREPFER | Hypoimmunogenic rhd negative primary t cells |
| AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| CN115768445A (zh) * | 2021-07-01 | 2023-03-07 | 宁波茂行生物医药科技有限公司 | 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用 |
| WO2023287827A2 (en) | 2021-07-14 | 2023-01-19 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向ｃｄ４之病毒載體之用途 |
| CA3227613A1 (en) | 2021-08-11 | 2023-02-16 | William Dowdle | Inducible systems for altering gene expression in hypoimmunogenic cells |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| TW202342498A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科融合醣蛋白 |
| TW202342757A (zh) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | 經修飾副黏液病毒科附著醣蛋白 |
| WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765342B2 (en) * | 2012-04-11 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| WO2015142661A1 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Regulatable chimeric antigen receptor |
| SG11201610074YA (en) * | 2014-06-06 | 2016-12-29 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR20200018498A (ko) * | 2017-06-20 | 2020-02-19 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
-
2018
- 2018-06-28 CA CA3068444A patent/CA3068444A1/en active Pending
- 2018-06-28 US US16/626,991 patent/US20200138865A1/en not_active Abandoned
- 2018-06-28 ES ES18759189T patent/ES2928296T3/es active Active
- 2018-06-28 CN CN201880044208.XA patent/CN111094345B/zh active Active
- 2018-06-28 AU AU2018291128A patent/AU2018291128A1/en active Pending
- 2018-06-28 SG SG11201913175TA patent/SG11201913175TA/en unknown
- 2018-06-28 KR KR1020207002752A patent/KR20200049757A/ko not_active Application Discontinuation
- 2018-06-28 WO PCT/US2018/039917 patent/WO2019006072A1/en active Application Filing
- 2018-06-28 EP EP18759189.6A patent/EP3645568B1/en active Active
- 2018-06-28 JP JP2019572798A patent/JP7288405B2/ja active Active
- 2018-06-28 EP EP22187063.7A patent/EP4159762A1/en active Pending
- 2018-06-28 IL IL271597A patent/IL271597B2/en unknown
-
2023
- 2023-02-13 JP JP2023020373A patent/JP2023071729A/ja active Pending
- 2023-11-30 US US18/524,799 patent/US20240091264A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529841A5 (ja) | ||
| JP2023071729A5 (ja) | ||
| US20240024359A1 (en) | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20 | |
| JP2020513754A5 (ja) | ||
| JP2022109953A5 (ja) | ||
| JP2016502512A5 (ja) | ||
| JP2020048588A (ja) | キメラ抗原受容体 | |
| RU2022103665A (ru) | Химерные конструкции антитело/t-клеточный рецептор и их применения | |
| JP2019514361A5 (ja) | ||
| JP2017537627A5 (ja) | ||
| JP2019528769A5 (ja) | ||
| JP2019522490A5 (ja) | ||
| JP2017537622A5 (ja) | ||
| JP2018525033A5 (ja) | ||
| JP2019500848A5 (ja) | ||
| JP2018529380A5 (ja) | ||
| JP2019522465A5 (ja) | ||
| ES2843599T3 (es) | Receptor de antígeno quimérico | |
| RU2014144143A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток | |
| JP2018504145A5 (ja) | ||
| JP2018508219A5 (ja) | ||
| JP2018505139A5 (ja) | ||
| JP2019508444A5 (ja) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2017509335A5 (ja) |